Summit Therapeutics (NASDAQ:SMMT) traded higher for the fifth straight session on Thursday as investors continued to cheer the latest trial data for its lead asset, ivonescimab, which indicated an outperformance against tislelizumab, a PD-1 inhibitor marketed by BeiGene (